Rhythm Pharmaceuticals Inc.
06/25/2026 | Press release | Distributed by Public on 06/25/2026 14:46
Proxy Results (Form 8-K)
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 24, 2026, Rhythm Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the close of business on the April 27, 2026 record date (the "Record Date") for the Annual Meeting, there were (i) 68,530,107 shares of the Company's common stock outstanding, of which each share of common stock was entitled to one vote; and (ii) 115,000 shares of the Company's Series A convertible preferred stock ("Convertible Preferred Stock") outstanding, of which 55,000 shares were entitled to vote, each share of Convertible Preferred Stock being entitled to a number of votes equal to 20.8333 shares of common stock per $1,000 liquidation preference of Series A convertible preferred stock (or 1,145,831 total votes). As a result, there were a total of 69,675,938 eligible votes as of the record date. A total of 64,146,146 votes were present online or represented by proxy at the Annual Meeting, representing approximately 92% of the total eligible votes as of the Record Date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Definitive Proxy Statement.
Rhythm Pharmaceuticals Inc. published this content on June 25, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 25, 2026 at 20:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]